Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

Conditions

• Glioblastoma
• Glioblastoma Multiforme
• Glioma
• Astrocytoma
• Brain Tumor

Interventions

• BIOLOGICAL: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
• BIOLOGICAL: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab

Sponsor

Cedars-Sinai Medical Center